Toll-like receptor 8

Toll-like receptor 8
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	Toll-like receptor 8
Organism	Human
Uniprot	O00206
Location	Endosomal membrane

Toll-like receptor 8 is an endosomal pattern recognition receptor implicated in innate immunity and host defense. Discovered through comparative studies tying Drosophila innate pathways to mammalian systems, it is related to a family of leucine-rich repeat proteins that detect nucleic acid motifs from pathogens. TLR8 is expressed in immune cell subsets and contributes to proinflammatory signaling cascades important for responses to viral and bacterial infections.

Structure and expression

TLR8 is a type I transmembrane protein with an extracellular leucine-rich repeat ectodomain, a single transmembrane helix, and an intracellular Toll/IL-1 receptor (TIR) domain; structural studies intersect with work on X-ray crystallography, Cryo-electron microscopy, Takeda Pharmaceutical Company-funded collaborations, Max Planck Society research groups, and comparative analyses alongside receptors characterized by labs at University of California, San Francisco, Harvard University, and Massachusetts Institute of Technology. Expression profiling links TLR8 transcripts to human monocytes, myeloid dendritic cells, and neutrophils in datasets originating from consortia such as the Human Genome Project, ENCODE Project Consortium, and the 1000 Genomes Project; tissue distribution maps produced by teams at National Institutes of Health and Wellcome Trust Sanger Institute show enriched expression in lymphoid and myeloid compartments. Developmental and cell-type–specific regulation involves transcription factors studied in laboratories at Rockefeller University, Stanford University, and Cold Spring Harbor Laboratory that also investigate pattern recognition receptor families. Species differences—highlighted in comparative immunology papers from University of Tokyo and Imperial College London—show that rodent orthologs diverge in ligand responsiveness versus human receptor variants characterized in populations studied by Broad Institute cohorts.

Ligands and activation

TLR8 senses single-stranded RNA motifs and synthetic small-molecule agonists identified in screens performed at GlaxoSmithKline, Pfizer, and academic groups at Yale University and University College London; functional ligand studies commonly reference viral RNAs from Influenza A virus, Human immunodeficiency virus, and Zika virus as natural ligands, and chemically defined agonists such as imidazoquinolines developed through medicinal chemistry collaborations with AstraZeneca and Eli Lilly and Company. Activation requires ligand delivery to endosomal compartments, a process informed by endocytosis research at Johns Hopkins University and trafficking work from Vanderbilt University; co-factors including small nucleic acid–binding proteins characterized at Columbia University and endosomal acidification mechanisms studied at Rockefeller University influence receptor dimerization and conformational change. Structural pharmacology papers from groups at Scripps Research Institute and Karolinska Institutet have mapped binding pockets and species-specific differences affecting agonist selectivity.

Signaling pathways

Upon ligand-induced activation, the TIR domain engages adaptor proteins—principally MyD88—an interaction elucidated in foundational signaling work at Harvard Medical School, University of Cambridge, and University of Pennsylvania; downstream kinases and ubiquitin ligases characterized by researchers at University of Michigan and Duke University activate transcription factors including NF-κB and IRF family members, pathways first described in studies associated with Nobel Prize in Physiology or Medicine–related signaling frameworks. The cascade recruits IRAK kinases and TRAF6, triggering MAP kinase modules and cytokine gene transcription studied in cell systems from Institut Pasteur, Max Planck Institute for Infection Biology, and translational groups at Mayo Clinic. Cross-talk with other receptors—reported by consortia involving European Molecular Biology Laboratory and National Cancer Institute—modulates type I interferon production and inflammatory mediator release.

Biological functions and immune responses

TLR8 contributes to antiviral defense, modulation of adaptive immunity, and sensing of microbial nucleic acids; functional immunology studies from University of Oxford, University of Toronto, and Seoul National University link TLR8 activity to dendritic cell maturation, cytokine secretion profiles, and T cell polarization observed in infection models featuring Herpes simplex virus, Respiratory syncytial virus, and bacterial challenges studied at Centers for Disease Control and Prevention. In human systems, TLR8-mediated cytokines influence B cell activation and antibody responses explored by immunology groups at Fred Hutchinson Cancer Center and Dana-Farber Cancer Institute. Evolutionary immunology research comparing primate genomes from Smithsonian Institution and Max Planck Institute for Evolutionary Anthropology traces selection pressures on receptor loci and ties to host–pathogen coevolution.

Clinical significance and disease associations

Variants in the TLR8 locus have been associated with altered susceptibility to infectious diseases studied in cohorts from World Health Organization surveillance programs, case–control studies at Karolinska University Hospital, and population genetics work at Wellcome Sanger Institute; associations include differential outcomes in sepsis cohorts assembled by European Society of Intensive Care Medicine and chronic viral infection cohorts from National Institutes of Health. Dysregulated TLR8 signaling has been implicated in inflammatory and autoimmune conditions investigated in clinical research at Mayo Clinic, Cleveland Clinic, and academic centers such as University of California, San Diego, with links to exacerbated cytokine release syndromes reported during severe viral infections analyzed by teams at Johns Hopkins Bloomberg School of Public Health. Genetic studies published with participation from Broad Institute and International HapMap Project participants outline risk alleles and expression quantitative trait loci influencing receptor function.

Therapeutic targeting and modulators

Therapeutic modulation of TLR8 is pursued by pharmaceutical and biotech companies including GlaxoSmithKline, Pfizer, AstraZeneca, and startups spun out from research at Scripps Research Institute and Stanford University. Agonists are explored as vaccine adjuvants in trials run by institutions such as National Institutes of Health and Bill & Melinda Gates Foundation-funded programs to enhance antiviral immunity, while antagonists are in preclinical development for inflammatory disorders by teams at Novartis and academic drug-discovery centers like University of Cambridge. Clinical trials registries coordinated with European Medicines Agency and Food and Drug Administration document investigational agents, and translational research partnerships involving Wellcome Trust and Cancer Research UK assess combination strategies with checkpoint inhibitors and antiviral therapeutics.

Category:Pattern recognition receptors